Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dana Garner

Nurse Practitioner, Adult Health Glendale, AZ Nurse Practitioner

NPI 1285905315 CMS profile 10613604

18700 N 64Th Dr, Suite 208, Glendale, AZ 85308

Open in the dashboard

General payments

$2,299

92 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Garner of Glendale, AZ is reported in the CMS Open Payments database as having received $2,299 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $606 20
2024 General $502 22
2023 General $338 8
2022 General $198 10
2021 General $655 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Garner
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Dana Garner were reported at $606. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Dana Garner Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $655 $138 $43–$438 $132
2022 $198 $165 $54–$494 $149
2023 $338 $178 $61–$549 $160
2024 $502 $186 $62–$575 $164
2025 $606 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Organogenesis Inc. $771 32 payments
  2. AbbVie, Inc. $297 16 payments
  3. Surgenex LLC $209 2 payments
  4. Integra LifeSciences Corporation $170 1 payment
  5. Novo Nordisk Inc $160 4 payments
  6. MIMEDX Group, Inc. $111 7 payments
  7. Tactile Systems Technology Inc $90 5 payments
  8. Nestle HealthCare Nutrition Inc. $81 3 payments
  9. Lilly USA, LLC $79 4 payments
  10. Microtransponder, Inc. $43 1 payment
  11. Other $291 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,299 92 payments
Products named General payments · program years 2021–2025
  1. PURAPLY WOUND MATRIX $272 11 payments
  2. UBRELVY $248 12 payments
  3. SurGraft $209 2 payments
  4. SurMatrix $209 2 payments
  5. ArdeoGraft $209 2 payments
  6. PelloGraft $209 2 payments
  7. RenoGraft $209 2 payments
  8. PURAPLY AM $192 4 payments
  9. Integra Recon-Skin And Wound $170 1 payment
  10. Integra Recon-Skin And Wound $170 1 payment
  11. Other $1,597 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

105

Median for Nurse Practitioner: 389

Drug cost

$6,363

Median for Nurse Practitioner: $21,885

Branded share of claims

21.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 11 $4,422
Gentamicin Sulfate Generic 27 $1,142
Doxycycline Hyclate Generic 33 $501
Ciprofloxacin Hcl Generic 11 $123
Mupirocin Generic 11 $99
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $76

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$60,402

Medicare's payments for the services billed

Medicare patients

78

Average age 76

Services billed

913

44 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 42%
Atrial fibrillation 41%
Ischemic heart disease 35%
Chronic kidney disease 33%
Heart failure 31%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record